# Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses

Review · Liu Y, Li Y, Hu Q

- Archive id: doi:10.3390/vaccines11071142
- Published: 2023-06-24
- Venue: Vaccines
- DOI: https://doi.org/10.3390/vaccines11071142
- PMID: 37514957
- PMCID: PMC10383046
- Citations: 24
- Source URL: https://doi.org/10.3390/vaccines11071142
- PDF: https://europepmc.org/articles/PMC10383046/pdf
- Provenance: europepmc

## Abstract

Although conventional vaccine approaches have proven to be successful in preventing infectious diseases in past decades, for vaccine development against emerging/re-emerging viruses, one of the main challenges is rapid response in terms of design and manufacture. mRNA vaccines can be designed and produced within days, representing a powerful approach for developing vaccines. Furthermore, mRNA vaccines can be scaled up and may not have the risk of integration. mRNA vaccines are roughly divided into non-replicating mRNA vaccines and self-amplifying RNA (saRNA) vaccines. In this review, we provide an overview of saRNA vaccines, and discuss future directions and challenges in advancing this promising vaccine platform to combat emerging/re-emerging viruses.

_Abstract reproduced under CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)._

Topics: [mRNA Therapeutics & Cancer Vaccines](https://space-kitty.com/topics/mrna-cancer-vaccines)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.